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A B S T R A C T
Mitochondrial intermembrane space proteins CHCHD2 and CHCHD10 have roles in motor neuron diseases such
as amyotrophic lateral sclerosis, spinal muscular atrophy and axonal neuropathy and in Parkinson's disease.
They form a complex of unknown function. Here we address the importance of these two proteins in human
motor neurons. We show that gene edited human induced pluripotent stem cells (iPSC) lacking either CHCHD2
or CHCHD10 are viable and can be differentiated into functional motor neurons that fire spontaneous and
evoked action potentials. Mitochondria in knockout iPSC and motor neurons sustain ultrastructure but show
increased proton leakage and respiration, and reciprocal compensatory increases in CHCHD2 or CHCHD10.
Knockout motor neurons have largely overlapping transcriptome profiles compared to isogenic control line, in
particular for synaptic gene expression. Our results show that the absence of either CHCHD2 or CHCHD10 alters
mitochondrial respiration in human motor neurons, inducing similar compensatory responses. Thus, pathogenic
mechanisms may involve loss of synaptic function resulting from defective energy metabolism.
1. Introduction
Mitochondrial intermembrane space proteins CHCHD10 and
CHCHD2 of unknown function have gained wide interest after being
genetically associated to neurological diseases. Dominant CHCHD10
mutations underlie motor neuron phenotypes such as amyotrophic
lateral sclerosis (ALS), spinal muscular atrophy of Jokela type (SMAJ)
and axonal Charcot Marie Tooth disease (CMT2) (Bannwarth et al.,
2014; Müller et al., 2014; Auranen et al., 2015; Penttilä et al., 2015)
whereas dominant CHCHD2 mutations cause Parkinson's disease
(Funayama et al., 2015). Evidence for whether the mutations cause
disease through loss-of-function or toxic gain-of-function has been
provided by different studies depending on the model system used
(Anderson et al., 2019; Brockmann et al., 2018; Burstein et al., 2018;
Genin et al., 2016; Meng et al., 2017).
Human CHCHD2 and CHCHD10 originated from a gene duplication
event (Cavallaro, 2010). Nuclear genes encode these small CHCH (coiled-
coil-helix-coiled-coil helix) domain proteins that are imported into the mi-
tochondrial intermembrane space by the redox-regulated MIA40 pathway
(Becker et al., 2012). Both proteins are conserved in metazoans (Longen
et al., 2009) but their exact function is unknown. They migrate in the same
high molecular weight complex (Burstein et al., 2018; Straub et al., 2018)
and have been suggested to form heterodimers (Huang et al., 2018). Studies
with overexpression of wild type and mutant CHCHD10 and CHCHD2
proteins, and knockdown and knockout experiments have been reported in
various organisms and cultured cells, with different results depending on
the mutation, cell type and the gene manipulation method. Effects on mi-
tochondrial ultrastructure, cristae maintenance, or respiratory chain func-
tion have been identified in some (Genin et al., 2016; Huang et al., 2018;
Meng et al., 2017) but not in all studies (Burstein et al., 2018; Straub et al.,
2018). Some studies reported that CHCHD10 is part of the mitochondrial
contact site and cristae organizing system (MICOS) (Bannwarth et al., 2014;
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Genin et al., 2016; Zhou et al., 2018), while others did not find evidence for
it (Burstein et al., 2018; Huang et al., 2018; Straub et al., 2018). Role as a
chaperone for protein import or metal transport has been proposed for
CHCHD10 (Burstein et al., 2018), whereas CHCHD2 has been suggested to
localize also to the nucleus as a transcription factor for cytochrome c oxi-
dase subunit 4 (COX4I2) upon oxidative and hypoxic stress (Aras et al.,
2015).
Knockout mice lacking CHCHD2 or CHCHD10 had a normal life
span without pathological changes (Anderson et al., 2019; Burstein
et al., 2018; Meng et al., 2017). Unexpectedly, knock-in mice with the
disease-associated variant p.S59L CHCHD10 developed fatal cardio-
myopathy (Anderson et al., 2019; Genin et al., 2019). In the mice, a
toxic aggregation model was proposed for pathogenesis where mutant
CHCHD10 co-aggregates with CHCHD2 triggering the mitochondrial
integrated stress response (Anderson et al., 2019). However, a double
knockout mouse model of CHCHD10 and CHCHD2 was recently in-
troduced, which partially phenocopied the mutant S59L mouse phe-
notype with development of cardiomyopathy (Liu et al., 2019), sug-
gesting that the normal functions of these proteins, and not just
aggregates, are also relevant for pathogenesis. Nevertheless, the severe
heart phenotypes in mice but not in human patients indicate that
CHCHD10/2 biology somewhat differs between human and mice.
Here we generated knockouts of CHCHD2 or CHCHD10 in human in-
duced pluripotent stem cells (iPSC). Although CHCHD2 was previously
suggested to regulate neuroectodermal differentiation of human embryonic
stem cells and iPSC by priming the differentiation potential towards neu-
roectodermal lineage (Zhu et al., 2016), we show that human iPSC differ-
entiate into functional motor neurons in the absence of CHCHD2 or
CHCHD10. However, we found that motor neurons lacking either of these
proteins had increased mitochondrial proton leakage, and showed com-
pensatory responses in CHCHD10/CHCHD2 amount, mitochondrial re-
spiration and synaptic transcriptomes. Our results indicate that CHCHD2 or
CHCHD10 are not dispensable in human motor neurons.
2. Results
2.1. Human iPSC without CHCHD2 or CHCHD10 are viable and
pluripotent
We used CRISPR/Cas9 genome editing to generate knockouts (KO)
Fig. 1. Human iPSC are viable and pluripotent in absence of CHCHD2 or CHCHD10 (A) Schematic representation of genome editing strategy. CRISPR-Cas9 system
was used to target 5′UTR and exon 1. (B) Pluripotency was validated with immunocytochemical analysis of pluripotency markers Nanog and TRA-1-81. Dapi
indicates nuclear staining. Scale bar 50 μm. (C) qRT-PCR of pluripotency markers OCT4 and SOX2, normalized to GAPDH (n = 3). (D) Expression of CHCHD2 and
CHCHD10 in knockout iPSCs by qRT-PCR, normalized to GAPDH (n = 3 per clone). (E) Immunocytochemical analysis verifies knockout of CHCHD2 and CHCHD10.
Scale bar 20 μm. (F) Immunoblot and quantification of CHCHD10 and CHCHD2 levels from whole cell lysates. Quantification shows the average of three independent
experiments, normalized to mitochondrial HSP60. Quantifications of D10 KOs clones are shown as pooled results from 3 clones F3, G4 and F2. See also Fig. S1 for
results of individual D10KO clones and full immunoblots. Data are shown as mean ± SD, *P < .05.
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of CHCHD2 or CHCHD10 in human HEL46.11 parental iPSC line
(Trokovic et al., 2015) by using two guide RNAs targeted to the 5′ UTR
and exon 1 of these genes (Fig. 1A). Four independent KO lines were
obtained for CHCHD10 (D10KO; F3, F2, B9 and G4) and one for
CHCHD2 (D2KO). Pluripotency of KO iPSC lines was verified by im-
munocytochemistry with Nanog and TRA1-81 antibodies (Fig. 1B) and
by the mRNA expression of pluripotency markers OCT4 and SOX2
(Fig. 1C). Quantitative PCR showed complete absence of CHCHD2
mRNA in the D2KO line and absence of CHCHD10mRNA in D10KO line
G4, but D10KO lines F3 and F2 had 10% of residual CHCHD10 mRNA
expression (Fig. 1D, S1A). Nevertheless, none of the D10KO lines had
detectable CHCHD10 protein, and D2KO line had no CHCHD2 protein,
as demonstrated by immunostaining (Fig. 1E) and western blotting
(Fig. 1F). Quantification of the western blots indicated that CHCHD10
protein level was increased in the D2KO iPSC line in comparison to
parental line, whereas D10KO iPSC lines had unchanged CHCHD2
protein levels (Fig. 1F). We also detected higher molecular weight
bands in immunoblotting with CHCHD10 and CHCHD2 antibodies that
were absent in the corresponding KO cell lines (Fig. S1B and C).
Overall, these results suggested that CHCHD2 and CHCHD10 are not
essential for iPSC survival.
2.2. Increased mitochondrial proton leak in CHCHD2 and CHCHD10
knockout iPSC
Next, we investigated if the absence of CHCHD2 or CHCHD10 af-
fected mitochondria in iPSC. We performed blue native polyacrylamide
gel electrophoresis (BN-PAGE) to detect respiratory chain complexes
and found that the overall assembly or the amount of the complexes
were not consistently altered (Fig. 2A). Mitochondrial DNA amount in
the KO lines was comparable to the parental line (Fig. 2B). Transmis-
sion electron micrographs revealed similar mitochondrial ultrastructure
in KO iPSC lines as in the parental line (Fig. 2C). Next, we assessed
mitochondrial respiration using Seahorse Extracellular Flux Analyzer.
We found that the oxygen consumption rate (OCR) differed between
parental and KO iPSC lines (Fig. 2D), with the KO showing higher basal
(Fig. 2E) and maximal respiration (Fig. 2F) in each KO line compared to
the parental line (p < .0001). KO lines also had higher ATP-coupled
oxygen consumption (Fig. 2G) (p < .0001) as measured by inhibition
of ATP synthase with oligomycin, which led to smaller decrease in basal
respiration in KO iPSC than in parental iPSC. Furthermore, coupling of
ATP synthesis to substrate oxidation was reduced in KO iPSC, indicated
by increased proton leakage (Fig. 2H) (p < .0001). In addition, loss of
CHCHD2 or CHCHD10 led to reduced spare capacity, determined from
the increase of OCR after addition of uncoupling agent FCCP (Fig. 2I)
(p < .0001). Ratio between OCR and extracellular acidification rate
(ECAR) was systematically increased in the absence of CHCHD2 or
CHCHD10, suggesting that KO iPSC utilized the oxidative ATP pro-
duction more than the parental cells (Fig. 2J) (p < .0001). In sum-
mary, although we did not observe obvious changes in mitochondrial
ultrastructure or respiratory chain complexes in KO iPSC, the increased
proton leakage may indicate decreased mitochondrial inner membrane
integrity, which is compensated for by increased respiration. Finally,
luminescence based measurement of total intracellular content showed
similar ATP levels in KO and parental iPSC (Fig. 2K, see also S1D).
2.3. Knockout iPSC differentiate into motor neurons
To investigate if human iPSC can differentiate into spinal motor
neurons in the absence of CHCHD10 or CHCHD2, we followed the es-
tablished differentiation protocol (Guo et al., 2017; Maury et al., 2015)
using D2KO and three D10KO iPSC lines together with the parental
control line. All lines appeared to differentiate equally well, which we
verified for the neuronal differentiation by qRT-PCR of βIII-tubulin
(TUBB3) and neurofilament medium (NEFM) expression (Fig. 3A) and
by immunostaining with NEFM, microtubule-associated protein 2
(MAP2) and βIII-tubulin (TUJ1) antibodies (Figs. 3B, S3A). Differ-
entiation towards neuronal lineage was efficient as all DAPI-positive
cells were also positive for MAP2 (Fig. 3B) or TUJ1 (Fig. S3). Motor
neuronal identity of differentiated neurons was validated by analyzing
the expression levels of ISL LIM homeobox 1 (ISL1) and choline acet-
yltransferase (CHAT) by qRT-PCR (Fig. 3A), and by immunostaining
with ISL1 and motor neuron and pancreas homeobox protein 1 (HB9)/
Homeobox protein HB9 antibodies (Fig. 3B). ISL1 mRNA level was
higher in D2KO neurons in comparison to parental line (Fig. 2B),
however, we did not observe the same in RNA sequencing of another set
of differentiated neurons, showing that loss of CHCHD2 does not con-
sistently lead to increased ISL1. Approximately 50% of DAPI-positive
neurons showed pronounced HB9-positivity across all lines in each
imaged frame (Fig. 3C). Furthermore, we confirmed by immunostaining
that motor neuron markers SMI-32 and ChAT were expressed (Fig.
S3B).
Next, we used immunoblotting to detect the levels of CHCHD10 and
CHCHD2 in KO motor neurons. We observed a modest increase of
CHCHD2 in D10KO motor neurons (Fig. 3D), and a larger increase of
CHCHD10 in D2KO motor neurons (Fig. 3D). Higher molecular weight
bands that were absent in D10KO iPSCs were again detected by im-
munoblotting with the CHCHD10 antibody (Fig. S2A), and these were
also increased in D2KO neurons. The mRNA expression level of
CHCHD10 was also increased in D2KO neurons and CHCHD2 expression
in D10KO neurons (Fig. 3E). These results showed that human iPSCs
differentiate successfully into motor neurons in the absence of CHCHD2
or CHCHD10, with reciprocal compensatory elevation of the two pro-
teins. In particular, the increase of CHCHD10 was evident in CHCHD2
deficiency.
2.4. Knockout motor neurons fire action potentials
To evaluate whether the KO motor neurons were functional and had
normal electrophysiological properties, we tested them using whole-cell
patch clamp during seventh week of differentiation. Current-clamp
mode recordings of iPSC-derived motor neurons demonstrated that all
cell lines developed the ability to fire evoked action potentials in re-
sponse to current injections (Fig. 3F). Many neurons also fired action
potentials spontaneously, with similar frequency and amplitude re-
gardless of cell line (Table 1). We found no differences in membrane
potential threshold or frequency of firing in response to current injec-
tion (Fig. 3G, H). The waveform of individual action potentials was also
similar in all cell lines (Table 1). To investigate the Na+ and K+ cur-
rents in iPSC-derived motor neurons, we applied a series of depolarizing
steps while recording in a whole-cell voltage clamp mode (Fig. 3I). No
differences in the current-voltage properties of Na+/Ca2+-currents
(Fig. 3K) or K+ persistent current (Fig. 3J) were observed after nor-
malization to membrane capacitance (pA/pF). This indicated that loss
of CHCHD10 or CHCHD2 did not affect excitability of motor neurons.
We also evaluated passive membrane properties in voltage clamp mode.
Whole-cell capacitance (Cm) values were similar across parental control
and knockout iPSC-derived motor neurons, except in D10KO clone G4,
which showed a reduction (Table 1). We found no significant differ-
ences in the input resistance (Rin) of motor neurons. Analysis of passive
membrane properties and parameters of action potential firing in-
dicated that iPSC-derived knockout iPSC matured into functional neu-
rons similarly to parental control. This demonstrated that functional
motor neuron maturation was not compromised by the loss of CHCHD2
or CHCHD10, and thus these proteins were dispensable for human
motor neuron differentiation in vitro.
2.5. Mitochondrial respiration is affected by absence of CHCHD2 or
CHCHD10 in human motor neurons
We used transmission electron microscopy to examine how the
absence of CHCHD2 or CHCHD10 affected mitochondrial ultrastructure
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in human neuronal processes. We found abundant mitochondria in all
imaged neurites in each cell line, and mitochondrial ultrastructure was
similar in KO motor neurons in comparison to the parental control
(Fig. 4A). No significant differences in the length of mitochondria be-
tween parental control and D2KO or D10KO motor neurons were ob-
served (Fig. 4B). These results indicated that loss of CHCHD2 or
CHCHD10 does not affect mitochondrial ultrastructure, abundance or
length in human neurites.
Next, we tested if the absence of CHCHD2 or CHCHD10 alters motor
neuron bioenergetics. Again, OCR differed between KO and parental
motor neurons, although the difference was not as pronounced as in the
iPSC (Fig. 4C). The changes were, however, in the same direction as in
iPSC, with somewhat higher basal respiration (Fig. 4D) and ATP-cou-
pled oxygen consumption (Fig. 4F), but the increases were not sig-
nificant in all clones. However, proton leakage was higher in all KO
motor neurons in comparison to parental controls (Fig. 4G)
(p < .0001), whereas spare capacity was reduced (Fig. 4H)
(p < .001). The ratio between OCR and ECAR was not altered in KO
motor neurons (Fig. 4I), which is expected as motor neurons rely much
more on oxidative metabolism than iPSC. Overall, these results sug-
gested that CHCHD2 or CHCHD10 are not redundant for mitochondrial
respiration in human motor neurons.
2.6. CHCHD10 and CHCHD2 knockout motor neurons have overlapping
transcriptome profiles
Next, we assessed whether the loss of CHCHD2 or CHCHD10 had
any effect on global gene expression in iPSC-derived motor neurons. We
analyzed the mRNA expression of four independent D2KO, four D10KO
(G4), four D10KO (F3) and eight parental control motor neuron cul-
tures. Comparison of our parental motor neuron RNA sequencing da-
taset by principal component analysis (PCA) to available human iPSC-
motor neuron datasets (GSE108094 (Rizzo et al., 2019), GSE121069
(Nijssen et al., 2018)) and laser captured post mortem human motor
neuron datasets (GSE76220 (Batra et al., 2016), GSE76514
(Nichterwitz et al., 2016), GSE93939 (Allodi et al., 2019)) showed tight
clustering of our 8 samples together, supporting consistent, high-quality
differentiation conditions of our cultures (Fig. 5A). Interestingly, PCA of
our samples showed that the expression profiles of the full D2KO and
D10KO motor neurons complete overlapped and were separate from
parental control motor neurons (Fig. 5B). Of note, D10KO clone F3,
which was a partial knockout having 11% residual CHCHD10 mRNA
expression, showed an intermediate expression profile between full KO
(clone G4) and parental control (Fig. S4A), but had consistent differ-
entially expressed genes with the full D10KO (Fig. S4B).
Differential gene expression (DE) analysis by DESeq2 was used to
compare full D2KO and D10KO motor neuron transcriptomes to those
of parental control. Motor neurons from both KO lines had ~3000
differentially expressed genes (false discovery rate (FDR) < 0.01)
compared to parental control motor neurons, and the majority of these
changes (> 65%) were shared between the knockouts (Fig. 5C, Table
S3). In contrast, only 175 genes were differentially expressed between
D2KO and D10KO samples. These results indicated that knockout of
either CHCHD2 or CHCHD10 produced similar effects on motor neuron
transcriptome.
Among individual genes that were highly and significantly upre-
gulated in both KO motor neurons in comparison to parental control
motor neurons were dipeptidyl peptidase like 6 (DPP6) (log2FC = 3.5,
FDR = 4.4E−103) and Ly6/neurotoxin 1 (LYNX1) (log2FC = 2.95 in
D2KO and log2FC = 2.6 in D10KO, FDR = 1.5E−259). We validated
these findings by qRT-PCR using samples from independent motor
neuron cultures (Fig. 5D). We also noted a reduction of transferrin (TF)
expression in KO motor neurons (log2FC = −2.8 FDR = 2.5E-125).
To identify cellular pathways that were altered by the loss of
CHCHD2 or CHCHD10, we used enrichment analysis (Fig. 5E, Table
S4). We did not detect enrichment of mitochondria-related pathways,
indicating that loss of CHCHD2 or CHCHD10 did not result in tran-
scriptional compensation of mitochondrial functions in human motor
neurons. Interestingly, GO term enrichments demonstrated pathways
related to neuronal developmental and synapse function, and to ion
channel activities, although we had not detected any changes in the
ability of the KO motor neurons to fire evoked action potentials. We
detected a reduction in several ionotropic glutamate receptor subunits,
such as GRIA1 (AMPA-type receptor subunit), and GRIK5 (kainate-type
receptor subunit), and in NMDA-type glutamate receptor subunits
GRIN2D, GRIN3A and GRIN3B, except GRIN1 that was upregulated. We
verified the decrease in GRIA1 expression in several D10KO clones by
qRT-PCR (Fig. 5G). In addition, several metabotropic glutamate re-
ceptor subunits, such as GRM2, GRM3, GRM4 and GRM7, were upre-
gulated (Fig. 5F). In addition, we detected significant changes in the
expression of several ion-channel subunits (Fig. S4C). K+ − channel
subunits (KCNK3, KCND2, KCNJ3, KCNIPA and KCNT1), Na+ channel
subunits (SCN1A and SCN4B) and Ca2+ channel subunits (CACNG3 and
CACNG8) were all significantly downregulated. On the contrary, Ca2+
channel subunits (CACNB2, CACNA1I and CACNA1G) and
Na+ − channel subunit SCN1B were all significantly upregulated (Fig.
S4C).
To assess the functional outcomes of reduction of AMPA receptor
expression in KO motor neurons, we measured miniature excitatory
postsynaptic currents (mEPSCs) by whole-cell patch-clamp in voltage
clamp mode (Fig. 5H). In the absence of muscle cells, motor neurons in
culture innervate each other with glutamatergic synapses, which we
confirmed by recording spontaneous EPSCs in the presence of NBQX, a
specific inhibitor of AMPA receptors. In the presence of NBQX, all
EPSCs disappeared (data not shown). mEPSCs, recorded in the presence
of an inhibitor of action potential firing TTX and a blocker of GABAA
receptors picrotoxin, represent AMPA receptor-mediated currents after
spontaneous action potential-independent synaptic release of gluta-
mate. Kinetics of the AMPA receptor-mediated EPSCs were similar in
parental control and knockout cell lines (Table 2). The loss of CHCHD2
Fig. 2. Loss of CHCHD2 or CHCHD10 does not disturb mitochondrial ultrastructure but affects mitochondrial respiration in iPSC. (A) Blue-native PAGE shows
unaltered mitochondrial respiratory chain complexes. Quantifications shown relative to average control levels. (B) mtDNA copy number was analyzed by qRT-PCR
(n = 3 per clone). (C) Electron micrographs showing intact mitochondrial ultrastructure in CHCHD2 and CHCHD10 knockout iPSC. Scale bar 0.5 μm. (D) Oxygen
consumption rate (OCR) measurement in iPSC using Seahorse XF96 Analyzer. Arrows indicate when mitochondrial inhibitors were added (n = 52–58 replicates/cell
line from three independent experiments). (E) Basal respiration. (F) Maximal respiration was assessed following mitochondrial uncoupling by FCCP. (G) ATP-coupled
respiration was determined after inhibition of ATP synthase by oligomycin. (H) Proton leakage indicates remaining OCR after inhibiting complex I and III by rotenone
and antimycin-A. (I) Spare respiratory capacity is determined by the difference between maximal and basal OCR. (J) Ratio between OCR and extracellular acid-
ification rate (ECAR) as an indication of oxidative and glycolytic ATP production, respectively. (K) Total ATP content per 1000 cells. See also Fig. S1C for total ATP
results of individual D10 KO clones. Quantifications for D10KO are shown as pooled results from clones F3, G4 and F2. Data are shown as mean ± SD, *P < .05.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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or CHCHD10 did not alter the amplitude of mEPSCs, which indicates
that the quantal size of glutamate release and density of functional
APMA receptors were not affected in the KO cell lines.
3. Discussion
The function of CHCHD10 and CHCHD2 proteins and the mechan-
isms by which the dominant pathogenic mutations in the corresponding
genes cause neurological diseases have been under intense research.
Studies have suggested that mice lacking CHCHD10 or CHCHD2 de-
velop normally and show no pathologies (Anderson et al., 2019;
Burstein et al., 2018; Meng et al., 2017), supporting gain-of-function
mechanism for the dominant patient mutations. CHCHD10 knock-in
mice carrying a pathogenic patient mutation, however, died of a severe
cardiomyopathy (Anderson et al., 2019; Genin et al., 2019), whereas
cardiac phenotypes have not been reported in patients (Penttilä et al.,
2017). This suggests that besides mice relevant human cell types should
be studied for CHCHD10 and CHCHD2 function and defects. Here we
utilized iPSC technology that enabled us to address the importance of
CHCHD2 and CHCHD10 in human motor neurons, which are affected in
CHCHD10-associated phenotypes.
We used CRISPR/Cas9-based gene editing to generate iPSC clones
that were lacking either CHCHD2 or CHCHD10, and differentiated
those into motor neurons. Knockout motor neurons were compared to
neurons differentiated from parental iPSC line that had the identical
genome except for the edited gene. Our results showed that iPSC
lacking CHCHD2 or CHCHD10 were viable and pluripotent and that
CHCHD2 or CHCHD10 were dispensable for human motor neuron dif-
ferentiation in vitro. However, we found that mitochondrial respiration
was compromised by loss of either of these two intermembrane space
proteins both in iPSC and motor neurons, with compensatory effects.
First, we observed reciprocal compensatory increases in CHCHD10
or CHCHD2 amounts. In particular, CHCHD2 absence was compensated
for by CHCHD10 increase in both human iPSC and motor neurons. Also
a knockout study in HEK293 cells found reciprocal compensatory re-
sponses to loss of either protein (Huang et al., 2018). Compensation
may explain why mature motor neurons lacking one of the proteins
could be generated. It is, however, possible that double knockout motor
neurons would also be functional. We were not successful in generating
double knockout iPSC lines in this study and currently are unable to
conclude that such iPSC would not be viable. When considering gene
therapy options for the dominant CHCHD10/2 mutations, it may be
beneficial to know that human motor neurons show reciprocal com-
pensatory responses when the amount of one of the proteins is reduced.
Secondly, although we did not observe changes in mitochondrial
ultrastructure in D2KO or D10KO iPSC or motor neurons, mitochondrial
proton leakage and respiration were increased in the knockouts. This
finding indicates that CHCHD2-CHCHD10 complex is required for ef-
ficient mitochondrial respiration, as also suggested by other recent
studies (Straub et al. (2018), Burstein et al. (2018) and Xiao et al.
(2019)). Increased mitochondrial respiration is likely to be a compen-
satory effect on less efficient ATP production, caused by increased
proton leakage. iPSC are mostly glycolytic (Prigione et al., 2010; Zhang
et al., 2011), and thus appeared to have more capacity for compensa-
tion than the motor neurons.
Thirdly, although the functionality of cultured knockout motor
neurons, as measured by patch-clamp methods, was not affected, D2KO
and D10KO motor neurons had largely overlapping transcriptome al-
terations. In particular, we found an enrichment of genes in synapse
function and synaptic membrane pathways. We suggest that these
changes are also compensation for the altered mitochondrial function.
We detected upregulation of a subset of metabotropic glutamate re-
ceptor subunits, whereas ionotropic subunits were mostly down-
regulated. Expression of GRIA1, which encodes the glutamate iono-
tropic receptor AMPA type subunit 1, was systematically decreased in
knockout motor neurons. Differential expression of glutamate receptor
subunits could alter synaptic transmission, however, we did not observe
any alterations in the amplitude of mEPCSs when comparing KO motor
neurons to parental control, indicating that the quantal size of neuro-
transmitter release or density of postsynaptic receptors was not af-
fected. It is possible that the increased metabotropic subunit expression
compensated for the downregulation of GRIA1. Even though
Fig. 3. CHCHD2 and CHCHD10 knockout iPSC differentiate into functionally active motor neurons. (A) Validation of the expression of neural transcripts TUBB3 and
NEFM and motor neural transcripts ISL1 and CHAT by qRT-PCR, normalized to GAPDH, on the day 37 of motor neuron differentiation (n = 3 per clone). (B)
Immunocytochemical analysis of ISL1 (red), NEFM (green), MAP2 (green) and HB9 (red) in neuronal cultures. Scale bars 50 μm. Dapi indicates nuclear staining. (C)
Manual counting of HB9-positive nuclei in relation to Dapi-positive cells. Total cells counted in 3 frames (n = 52–185 per clone). (D) Immunoblot and quantification
of CHCHD2, CHCHD10, TUJ1 and NEFM from whole cell lysates. Quantification shows the results from two or three cultures per clone from two independent
experiments, normalized to GAPDH. (E) Expression of CHCHD2 and CHCHD10 in knockout iPSC-derived motor neurons by qRT-PCR, normalized to GAPDH (n = 3
per clone). (F) Representative traces of evoked action potentials of iPSC-derived motor neurons in response to current injections. (G) Threshold (mV) of action
potential firing (n = 11–20 per clone). (H) Action potential firing frequency (Hz) in response to incremental current injections (n = 11–20 per clone). (I)
Representative traces of Na+/Ca2+ and K+ currents, recorded at different membrane potentials. Na+/Ca2+ currents are also shown in inserts, using expanded time
scale. (J) Current/voltage relationship characteristics of persistent K+-current normalized to membrane capacitance (pA/pF) (n = 7–15 per clone). (K) Current/
voltage relationship characteristics of Na+/Ca2+ − current normalized to membrane capacitance (pA/pF) (n = 7–15 per clone). Quantifications of D10 KOs clones
are shown as pooled results from 3 clones F3, G4 and F2. See also Fig. S2 for full immunoblots. Data are shown as mean ± SD, except mean ± SEM in G-K,
*P < .05. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 1
Passive membrane properties and action potential firing in motor neurons.
Parental control (n) D2KO (n) D10KO F3 (n) D10 KO G4 (n)
Capacitance, pF 28.8 ± 3.1 (25) 22.0 ± 1.2 (26) 28.1 ± 1.6 (11) 20.5 ± 1.8 (21)*
Input resistance, MΩ 747.8 ± 93.1 (25) 827.0 ± 90.7 (26) 751.7 ± 110.6 (11) 958.2 ± 135.8 (21)
Resting membrane potential, mV −43.2 ± 2.0 (24) −41.4 ± 1.7 (22) −48.0 ± 1.8 (10) −42.9 ± 1.7 (16)
Spontaneous AP frequency, Hz 2.2 ± 0.4 (18) 2.6 ± 0.5 (13) 1.1 ± 0.3 (8) 2.8 ± 0.6 (14)
Spontaneous AP amplitude, mV 60.0 ± 3.8 (18) 54.5 ± 2.4 (13) 63.4 ± 3.9 (8) 53.4 ± 1.6 (14)
Rheobase, pA 24.8 ± 3.8 (20) 19.0 ± 1.9 (19) 27.3 ± 4.5 (11) 18.5 ± 2.2 (20)
Evoked AP amplitude, mV 59.7 ± 3.2 (20) 58.2 ± 2.9 (19) 56.9 ± 2.1 (11) 59.6 ± 2.3 (20)
Evoked AP half-width, ms 1.4 ± 0.08 (20) 1.3 ± 0.06 (19) 1.2 ± 0.08 (11) 1.2 ± 0.04 (20)
After-hyperpolarization amplitude, mV 17.5 ± 2.1 (20) 15.8 ± 1.6 (19) 18.1 ± 1.1 (11) 16.7 ± 1.7 (20)
After-hyperpolarization decay time, ms 13.0 ± 0.9 (20) 13.2 ± 1.0 (19) 13.5 ± 1.9 (11) 11.5 ± 0.6 (20)
n = number of cells tested. *p < .05 compared to parental control.
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acetylcholine is the main neurotransmitter at neuromuscular junction
(NMJ), there are indications that glutamate might participate in mod-
ulating cholinergic transmission at vertebrate NMJ (Colombo, 2019),
where glutamate activates presynaptic ionotropic receptors leading to
increased release of acetylcholine to NMJ (Fu et al., 1995; Liou et al.,
1996). We also detected altered expression of several K+-, Na+- and
Ca2+-channel transcripts. Altered excitability has been proposed as one
of the underlying causes for ALS (Naujock et al., 2016; Wainger et al.,
2014).
We identified highly upregulated expression of DPP6, which en-
codes a single-pass type II membrane protein involved in trafficking of
voltage-gated potassium channels (Sun et al., 2011). GWAS associated
DPP6 with susceptibility to sporadic ALS (van Es et al., 2008), and DPP6
was found as one of the most increased transcripts in iPSC-motor
neurons from ALS patients with the C9ORF72 repeat expansion (Sareen
et al., 2013). Another highly upregulated gene in both knockouts was
LYNX1, which functions as an allosteric modulator of nicotinic acet-
ylcholine receptor, balancing neuronal activity and survival (Miwa
et al., 2006). We also saw a reduction of transferrin (TF) expression in
knockout motor neurons. Transferrin is an extracellular iron trans-
porter, balancing cellular iron uptake with efflux, and it is mainly ex-
pressed in liver but also in the nervous system. CHCHD10 knockdown
in HEK293 cells was shown to result in accumulation of in-
tramitochondrial iron, leading to a suggestion of CHCHD10 to function
as a chaperone in mitochondrial iron import (Burstein et al., 2018).
Whether iron levels and transferrin have a role in motor neurons in
CHCHD10/2-deficiency remains to be studied.
Taken together, we propose that although functional human motor
neuron differentiation in vitro does not require CHCHD2 or CHCHD10,
these proteins are not dispensable in motor neuron mitochondria, and
their loss results in compensatory responses in respiration and in
transcriptional regulation of synaptic function. Whether the insufficient
energy metabolism is enough to compromise function for example in a
late-onset manner, or in combination with a postsynaptic defect, is not
yet known.
Interestingly, a new muscle-specific Chchd10 knockout mouse
showed motor defects, abnormal neuromuscular transmission and NMJ
structure, suggesting that CHCHD10 has an important role at the per-
ipheral synapse (Xiao et al., 2019). Similarly, the CHCHD10 knockin
mice had severe NMJ degeneration and motor behavior defects
(Anderson et al., 2019; Genin et al., 2019). Co-cultures of iPSC-derived
motor neurons and myotubes could be used to verify whether human
NMJ formation is also affected by CHCHD10/2 defects. It is also pos-
sible that both the motor neurons and muscle cells contribute to the
dying-back motor neuronopathy, as was reported in the case of FUS-
ALS, which revealed endplate maturation defects (Picchiarelli et al.,
2019). Future studies using more complex culture systems, which better
mimic the physiological environment and interactions of motor neu-
rons, are required to address the consequences that the identified sy-
naptic alterations may have in deficiency of CHCHD2 and CHCHD10.
Furthermore, iPSC-based models of the human disease variants that
cause motor neuron disease phenotypes or Parkinson's disease should
be compared to the knockout models to gain further understanding of
the genetic mechanisms of the diseases.
In conclusion, we have presented functional differentiation of
human iPSC-derived motor neurons in the absence of CHCHD10 or
CHCHD2, with compensatory effects. Similar effects on respiration and
transcriptome profiles in both knockouts support a similar role for the
two proteins in the mitochondria of motor neurons.
4. Experimental procedures
4.1. Ethical approval
The generation of the human induced pluripotent stem cell lines
used in this study was approved by the Coordinating Ethics Committee
of the Helsinki and Uusimaa Hospital District (Nro 423/13/03/00/08)
with informed consent of the donor.
4.2. Induced pluripotent stem cells (iPSC)
The reprogramming of human neonatal foreskin fibroblasts from
healthy control (HEL46.11) into pluripotent stem cells by Sendai virus
technology has been done at Biomedicum Stem Cell Center (University
of Helsinki, Finland), as previously described (Trokovic et al., 2015),
and the pluripotency confirmed in previous studies (Saarimäki-Vire
et al., 2017; Weltner et al., 2018). Cells were cultured at 37 °C in 5%
CO2, 20% O2. Using the HEL46.11 iPSC line as the parental control, we
generated one D2KO clone and four D10KO clones (F3, F2, G4 and B9),
of which we used F3, F2 and G4 in most of the studies. IPSC were
maintained on Matrigel-coated (Corning) plates with E8-medium
(Gibco) supplemented with E8-supplement (Gibco). IPSC were passaged
with 0.5 mM EDTA (Invitrogen) in phosphate-buffer saline (PBS) when
confluent. Pluripotency of the generated knockout iPSC lines was con-
firmed with immunostaining with Nanog (1:250 dilution, D73G4, Cell
Signaling) and TRA-1-81 (1:100, MA1-024, ThermoFisher) antibodies.
In addition, expression levels of OCT4 and SOX2 were analyzed by qRT-
PCR.
4.3. Genome editing of iPSC
CRISPR-SpCas9 technology was used to generate D2KO and D10KO
iPSC. GuideRNA (gRNAs) sequences were designed using web-based
tools from http://crispr.mit.edu (Hsu et al., 2013) and https://
benchling.com (Benchling [Biology Software], 2018). The gRNAs
were designed to target 5′UTR and the first exon. Transcriptional units
for gRNA expression were prepared by PCR amplification and further
concatenated using Golden Gate assembly as described in (Balboa et al.,
2015), detailed protocol is provided by Addgene (http://www.addgene.
org/78311/). Different gRNA pairs were first tested by co-transfection
with wild type spCas9 expressing the plasmid CAG-Cas9-T2A-EGFP-
ires-puro (Addgene plasmid #78311) into HEK293 cells. The genomic
region flanking gRNA target sites was amplified with a pair of gene
specific primers and editing efficiency was detected by agarose gel
electrophoresis.
Sequences (5′-TGGAAGAGCAGGACGTCACG-3′) and (5′-GTGCGGC
TTCGGCTTCCACG-3′) in the 5′UTR and first exon, respectively, were
chosen for the CRISPR-SpCas9 targeting sites in CHCHD2. Similarly,
gRNAs used to create CHCHD10 knockout were (5′-TCTGTTAGGACC
ACCGCAGA-3′) and (5′-GCCGCGCTGCGGCTTCCCCG-3′). Genome
editing was done essentially as described in (Saarimäki-Vire et al.,
2017). Briefly, two million HEL46.11 cells were electroporated with
Fig. 4. CHCHD2 and CHCHD10 are not dispensable for mitochondrial respiration in human iPSC-derived motor neurons. (A) Ultrastructure analysis by transmission
electron microscopy of parental control, D2KO and two D10KO (clones F3 and G4) iPSC-derived motor neurons at day 38. The right panel of each image is a
magnification of the area indicated by the square in the left panel. Representative images of motor neuron neurites are shown. Scale bars are indicated. (B)
Quantification of mitochondrial length (μm) in electron micrographs (n = 80–143 per clone). (C) OCR in iPSC-derived motor neurons. Arrows indicate when
mitochondrial inhibitors were added. (D) Basal respiration. (E) Maximal respiration was assessed following mitochondrial uncoupling by FCCP. (F) ATP-coupled
respiration was determined after inhibition of ATP synthase by oligomycin. (G) Proton leakage indicates remaining OCR after inhibiting complex I and III by rotenone
and antimycin-A. (H) Spare respiratory capacity (%) is determined by the difference between maximal and basal OCR. (I) Ratio between OCR and extracellular
acidification rate (ECAR). Data represent mean ± SD, *P < .05, individual data points are shown from two independent experiments (n = 28–42 replicates/cell
line).
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Fig. 5. CHCHD2 and CHCHD10 knockout motor neuron transcriptome profiles are overlapping and show altered synaptic gene expression. (A) Comparison of our
RNA sequencing dataset by principal component analysis (PCA) to available human iPSC-motor neuron and laser captured post mortem human motor neurons. (B)
PCA of motor neurons of this study show overlap for D2KO and D10KO motor neurons (n = 8 for parental control (WT) and n = 4 for each KO). (C) Venn diagram
displaying the number of significantly altered genes (FDR < 0.01) in D10KO vs. WT, D2KO vs. D10KO and D2KO vs. WT samples. (D) Mean reads of DPP6 and
LYNX1 in RNA sequencing dataset (left panels), and expression of the same genes by qRT-PCR (right panels) from independent samples (n = 3 per clone). (E) GO
term enriched pathways in D10KO vs. WT and D2KO vs. WT comparisons. Up- and downregulated pathways are indicated by gene ratio and FDR. (F) Significantly
altered (FDR < 0.01) glutamate receptor subunits. Mean reads from RNA sequencing were normalized to parental control level, shown as relative expression. (G)
qRT-PCR of GRIA1 normalized to GAPDH. Individual D10 KO clones shown (n = 3 independent experiments). (H) Amplitudes (pA) of miniature excitatory post-
synaptic currents (mEPSCs) (n = 11–17 per clone) and representative traces of mEPSCs. Data are shown as mean ± SD, * P < .05.
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3 μg of CAG-Cas9-T2A-EGFP-ires-puro endotoxin-free plasmid and
500 ng of each gRNA (Neon Transfection System, 1100 V, 20 ms, two
pulses, Thermo Fisher Scientific). Electroporated cells were im-
mediately plated onto prewarmed Matrigel-coated plates containing
E8-medium with 10 μM ROCK inhibitor (ROCKi) (Y-27632 2HCl, Sell-
eckchem). Alive, singlet cells positive for GFP fluorescence were sorted
on 96-well Matrigel-coated plates containing E8 medium supplemented
with 5 μM ROCKi and CloneR™ (StemCell Technologies) using BDInflux
Flow Cytometer at the Biomedicum Flow Cytometry Unit (University of
Helsinki, Finland). Expandable iPSC colonies were screened by PCR
followed by sequencing and subsequently by western blotting.
4.4. Motor neuron differentiation
To differentiate iPSCs into motor neurons, we used the protocol by
(Guo et al., 2017; Maury et al., 2015) with slight modifications. Briefly,
to obtain neuroepithelial stem cells, iPSC were dissociated with Accu-
tase (Gibco) into small clusters and resuspended in E8 medium con-
taining 5 μM Y-27632 (Selleckchem). The following day, medium was
changed to Neuronal basal medium (DMEM F12, Neurobasal vol:vol,
with N2 (Life Technologies), B27 (Life technologies) and L-ascorbic acid
0.1 mM (Santa Cruz)) supplemented with 40 μM SB431542 (Merck),
0.2 μM LDN-193189 (Merck/Sigma), 3 μM CHIR99021 (Selleckchem),
and 5 μM Y-27632 (Selleckchem). From day 3 on, 0.1 μM retinoic acid
(Fisher) and 0.5 μM SAG (Calbiochem) was added to neurobasal
medium. From day 7 on, BDNF (10 ng/ml, Peprotech) and GDNF
(10 ng/ml, Peprotech) were added. 20μM DAPT (Calbiochem) was
added on day 9. Motor neuron progenitor spheroids were dissociated
into single cells for plating on day 11 by using Accumax (Invitrogen).
Motor neuron progenitors were subsequently plated on poly-D-lysine
50 μg/ml (Merck Millipore) and laminin 10 μg/ml (Sigma-Aldrich)
coated plates at 5 × 104 cells per cm2. At day 14 retinoic acid and SAG
were removed from media. From day 16 on, the cells were switched to
motor neuron maturation medium supplemented with BDNF, GDNF,
and CNTF (each 10 ng/ml, Peprotech). Media were changed every other
day by replacing half of the medium. Motor neurons were ISL1-positive
around day 30 of differentiation, after which they were considered
mature. Motor neurons were used in experiments at week 5, except at
week 7 in patch clamp.
4.5. Immunoblotting
For protein analysis iPSC and iPSC-derived motor neurons were
manually collected by scraping on ice and samples were maintained at
−80 °C until further processing. For western blot, total protein from
motor neuronal and iPSC cultures were harvested with RIPA buffer
(Thermo Fisher) supplemented with Halt™ protease inhibitor (Thermo
Scientific). Protein concentration was quantified with BCA assay
(Pierce) according to manufacturer's instructions. 10 μg of protein/
sample was run on TGX 10% and 4–20% acrylamide gels (Bio-Rad) and
transferred to 0.2 μm PVDF-membrane (Bio-Rad) with the TransBlot
Turbo transfer system (Bio-Rad). Membrane was blocked with 5% milk/
TBS-T for 1 h RT. The primary and secondary antibodies are listed in
supplementary materials. Signal was detected with ECL reagent
(Thermo Scientific) and membranes were imaged with Chemidoc XRS
+ (Bio-Rad). Image Lab Software (BioRad) was used to quantify the
band intensities. For quantification, band intensities were normalized
to GAPDH or HSP60.
Assembly of mitochondrial respiratory chain complexes were in-
vestigated using Blue-Native-PAGE in mitochondria extracted from
iPSC as described by (Konovalova, 2019), using primary and secondary
antibodies listed in supplementary materials.
4.6. Quantitative PCR (qPCR) based determination of mitochondrial DNA
copy number
DNA was extracted with Macherey-Nagel™ NucleoSpin™. 25 ng of
DNA was used for the qPCR reaction. Levels of mitochondrial tRNA-LEU
(UUR) (MT-TL1) and nuclear B2M were analyzed by qPCR amplifica-
tion in CFX Real-time system C1000Touch (Bio-Rad) with SYBR-green
Flash (Thermo Fisher) by transcript specific primers. The ratio between
MT-TL1 and B2M transcripts were used to determine the copy number
of mtDNA. The ratio between mitochondrial cytochrome B (MT-CYTB)
or nuclear ACTB transcripts were used to verify results.
4.7. Immunocytochemistry
IPSC and iPSC-derived motor neuronal cultures on cover glasses
were fixed with 4% paraformaldehyde (PFA) for 15 min at RT and then
permeabilized with PBS containing 0.2% Triton X-100 (Fisher) for
10 min. Cells were blocked with 5% protease-free BSA (Jackson
Immuno Research) in 0.1% Tween20 in PBS (PBS-T) for 2 h in RT. Cells
were incubated overnight at +4 °C in blocking buffer (5% bovine
serum) containing different primary antibodies, listed in supplementary
materials. After washing with PBS-T, cells were incubated with sec-
ondary antibody for 1 h at RT. Cover glasses were applied on micro-
scope slides with Vectashield DAPI (#H-1200) and imaged with Axio
Observer Z1 (Zeiss) inverted fluorescence microscope.
IPSCs with CHCHD2/10 (Alexa 488) staining were imaged with
LSM880 IndiMo Axio Observed laser scanning confocal microscope
with Plan-Apochromat 63×/1.4 oil DIC M27 immersion lense.
CHCHD2/10 channel was captured with 488 laser using the same set-
tings and exposure time for all samples (laser 3.06%). Images were
acquired at 16-bit depth and 1912-x1912 frame size. The results were
visualized with Zen Blue software.
4.8. Quantitative reverse transcription PCR (qRT-PCR)
RNA from differentiated motor neuronal cultures was isolated using
NucleoSpin RNA extraction kit (Macherey-Nagel). RNA was reverse
transcribed with Maxima first strand cDNA synthesis kit (Thermo
Fisher). cDNA levels were analyzed by qRT-PCR amplification in CFX
Real-time system C1000T (Bio-Rad) with SYBR green Flash (Thermo
Fisher) by transcript specific primers. Technical duplicates were used
for all studies. 2 ng of cDNA was used for total mRNA quantification.
Relative quantification was done using the ΔΔCt method with nor-
malization to GAPDH. A list of primers can be found at supplementary
methods.
4.9. Transmission electron microscopy (TEM)
Motor neuronal cultures on glass slides/cover glasses were fixed
Table 2
Kinetics of the AMPA receptor-mediated EPSCs.
Parental control (n) D2KO (n) D10KO F3 (n) D10KO G4 (n)
Rise time, ms 2.08 ± 0.25 (15) 2.80 ± 0.45 (17) 1.39 ± 0.16 (11) 2.00 ± 0.33 (15)
Decay time, ms 2.67 ± 0.35 (15) 3.55 ± 0.58 (17) 1.61 ± 0.15 (11) 2.45 ± 0.36 (15)
Peak half-width, ms 1.28 ± 0.15 (15) 1.58 ± 0.23 (17) 0.77 ± 0.07 (11) 1.21 ± 0.18 (15)
n = number of cells tested. *p < .05 compared to parental control.
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with 2% glutaraldehyde in 0.1 M NaCac buffer for 30 min at RT, and
then washed with NaCac buffer. Cells were kept in NaCac buffer at
+4 °C until further use. iPSC on glass slides were fixed with 2%
PFA + 2% Glutaraldehyde (Sigma) for 30 min at 4 °C, then washed
once with PBS and fixed with 2% Glutaraldehyde O/N at 4 °C. Fixed
neurons and iPSC were prepared according to standard protocols for
transmission electron microscopy. Ultrathin sections were observed
with Jeol 1400 transmission electron microscope at 80000 V. ImageJ
(https://imagej.nih.gov/ij/) package Fiji (Schindelin et al., 2012) was
used to assess mitochondria length.
4.10. ATP assay
Intracellular ATP levels of iPSCs were quantified using an ATPlite
assay kit (PerkinElmer). IPSCs were dissociated with Accutase (Gibco)
and cell suspension containing 15,000 cells was added to 96-well mi-
croplate. IPSCs were processed according to manufacturer's instruc-
tions. Briefly, cells were lysed with mammalian lysis solution at orbital
shaker 700 rpm for 5 min. After lysis, ATP substrate was added and
mixed at orbital shaker 700 rpm for 5 min. Plate was allowed to dark
adapt for 10 min, after which luminescence intensities were monitored
with EnSpire (PerkinElmer) microplate reader with 0.1 s measurement
time. Total ATP amount was quantified from ATP standard curve.
4.11. Oxygen consumption
Oxygen consumption rate in iPSC and iPSC-derived motor neurons was
measured using Seahorse XF96 Extracellular Flux Analyzer (Agilent) as
previously described in (Vandoorne et al., 2019). Briefly, IPSC were
seeded at density of 25,000 cells/well 24 h prior measurements on Ma-
trigel-coated (Corning) XF96 Seahorse plates in the presence of 10 μM Y-
27632 (Selleckchem) (Zhang et al., 2012). iPSC oxygen consumption rate
(OCR) was measured one day after seeding. At day 10 of differentiation
iPSC-derived motor neuron progenitors were seeded at density of 20,000
cells/well on poly-D-lysine and laminin coated XF96 Seahorse plates
(Agilent). Oxygen consumption rate (OCR) was measured at day 30 of
motor neuron differentiation. On the day of the assay, medium was re-
placed with Seahorse Base Medium supplemented with 1 mM pyruvate,
2 mM glutamine, 25 mM glucose and 5 mM HEPES, pH adjusted to 7.4. In
baseline conditions, three measurements of OCR were done, after which
ATP synthetase was inhibited by injection of oligomycin (Sigma) (con-
centration in well 1.5μM for iPSC and 2 μM for iPSC-derived motor neu-
rons). Oligomycin induced drop in baseline OCR reflects oxygen con-
sumption needed for ATP production. Next, uncoupler carbonilcyanide p-
triflouromethoxyphenylhydrazone (FCCP) (Sigma) was injected (con-
centration in well 0.25 μM for iPSC and 5 μM for iPSC derived motor
neurons). FCCP injection forces cells to use their maximal mitochondrial
capacity to maintain membrane potential and increase in OCR reflects the
spare respiratory capacity. Finally, electron transport chain was shut down
by inhibiting complex I and III activity by addition of rotenone (Sigma)
and antimycin-A (Sigma) at 1 μM concentration in well and remaining
OCR reflects non-mitochondrial oxygen consumption. Difference in OCR
between oligomycin and rotenone/antimycin-A injection indicates proton
leakage. After assay, iPSC were stained with Hoechst and OCR was nor-
malized to cell number using Cytation5 plate reader. iPSC-derived motor
neurons were normalized to DNA content using CyQUANT kit (In-
vitrogen). Three independent runs (two for motor neurons) were per-
formed, where each run contained 23 wells per cell line. Only those wells
with a homogeneous monolayer of iPSC or intact neuronal culture were
included in the analysis.
4.12. RNA sequencing
RNA was isolated from four independent motor neuron cultures per
knockout cell line (D2KO and D10KO G4 and F3) and from eight control
cultures at day 37 of differentiation. RNA was extracted with
Nucleospin RNA kit (Macherey-Nagel) according to manufacturer's in-
structions including rDNAse treatment. RNA concentration was mea-
sured with Qubit. RNA quality determination and mRNA sequencing
were done at Biomedicum Functional Genomics Unit with single-end
sequencing with poly(A) binding beads and NEBNext Ultra Directional
RNA Library Prep and sequenced with Illumina NextSeq High Output
1 × 75 bp.
Raw data was demultiplexed with bcl2fastq2 (v2.20.0.422;
Illumina). Adapter sequences (AGATCGGAAGAGCACACGTCTGAACTC
CAGTCA), low quality (Phred score < 25) and ambiquous bases (N)
were removed with cutadapt (v.2.2) (Martin, 2011), retaining reads
longer than 25 bp. The trimmed reads were mapped to the human re-
ference genome (GRCh38) with STAR (v. 2.5.3) (Dobin et al., 2013).
Gene expression was analyzed with R (v.3.6.0) (R Core Team, 2019).
The read counts for genes (mapping to exons) were extracted with
Rsubreads (v.1.34.6) (Liao et al., 2019) excluding duplicates, multi-
mapping reads, chimeric fragments, and reads with mapping quality
below 10.
Differential gene expression was analyzed with DESeq2 (v.1.24)
(Love et al., 2014), comparing D2KO and D10KO to parental cells. The
differentially expressed genes were analyzed for pathway enrichment
using the GO (Ashburner et al., 2000; The Gene Ontology Consortium,
2018), using ClusterProfiler (v3.12.0) (Yu et al., 2012). For enrichment
analysis, the set of background genes (universe) was limited to genes
expressed in our samples. Genes with low read depth (< 50 reads in
total) were excluded from the differential expression and enrichment
analysis.
RNA-seq data from the motor neurons in this study were contrasted
to publicly available datasets of other human iPSC derived motor
neurons; GSE108094 (Rizzo et al., 2019) and GSE121069 (Nijssen et al.,
2018) as well as laser captured motor neurons; GSE76220 (Batra et al.,
2016), GSE76514 (Nichterwitz et al., 2016) and GSE93939 (Allodi
et al., 2019). The same analysis procedures (trimming, mapping and
read counting) were applied to the reference samples as for our dataset.
Gene expression results were visualized with ggplot2 (v3.2.1)
(Wickham, 2016), limma (v3.40.6) (Ritchie et al., 2015) and eulerr
(v5.1.0) (Larsson, 2019).
4.13. Electrophysiology
Whole-cell patch-clamp recordings were done on living cells after
42 days in culture. Coverslips containing cultured neurons were placed
to recording chamber on the visually guided patch-clamp setup.
Temperature at the recording chamber was kept at 30 °C, and cells were
continuously perfused with ACSF of the following composition (mM):
124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 1 mM MgSO4, 26 mM
NaHCO3, 2 mM CaCl2, 15 mM glucose, and 95% O2/5% CO2.
Recordings were done with glass microelectrodes (4–6 MΩ), using
Multiclamp 700A amplifier (Axon Instruments, USA), and digitized at
20 kHz. Data were collected with Clampex 10.2 (Molecular Devices,
USA). Series resistance, input resistance and capacitance were recorded
in voltage clamp mode at −70 mV by injection of 5 mV voltage steps. If
series resistance exceeded 20 MΩ, or if the change in series resistance
during the experiment exceeded 30%, the recording was discarded.
For recording of passive membrane properties, voltage-gated cur-
rents and action potential firing microelectrodes were filled with the
intracellular solution containing (mM): 105 K gluconate, 15 KCl, 5.3
CaCl2, 5 NaCl, 10 HEPES, 10 EGTA, 4 MgATP, 0.5 Na2GTP, pH 7.2.
Voltage-gated sodium/calcium and potassium currents were recorded
in voltage clamp mode. Baseline voltage was set at −70 mV, and vol-
tage steps with the increasing increment of 10 mV were injected for
100 ms. Leak subtraction protocol was applied, and the current am-
plitude was analyzed after correction for leak current. Resting mem-
brane potential and spontaneous activity were recorded in current
clamp mode without any background current injected. For recording of
the evoked action potentials, baseline membrane potential was held at
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−60 mV, and depolarizing current steps with the increasing increment
of 10 pA were injected for 1 s.
Miniature excitatory synaptic currents (mEPSCs) were recorded in a
whole-cell voltage clamp configuration at −70 mV in ACSF containing
tetrodotoxin (TTX, 1 μM) and picrotoxin (100 μM). Presence of AMPA-
type glutamatergic synapses was confirmed by disappearance of spon-
taneous EPSCs by addition of NBQX (20 μM). Intracellular solution
contained (in mM): 110 CsMeSO3, 5.3 CaCl2, 5 NaCl, 10 HEPES, 10
EGTA, 5 lidocaine N-ethyl chloride, 4 MgATP, 0.5 Na2ATP.
Data were analyzed in Clampfit 10.2 (Molecular Devices, USA) and
MiniAnalysis program (Synaptosoft). Properties of individual evoked
action potentials were analyzed by a custom MATLAB script (MATLAB
R2018b, MathWorks, USA; Zubarev, Nagaeva, unpublished). Meta-
analysis was done in GraphPad Prism 8.
4.14. Statistical analysis
GraphPad Prism was used for all statistical analyses except RNA-seq.
Unless otherwise indicated, mean ± SD values are reported in the
graphs. One-way ANOVA was used for the experiments with post-hoc
Tukey's test to determine statistical differences between groups.
Student's unpaired two-tailed t-test was used to determine statistical
significance in OCR measurements. *P < .05 were considered sig-
nificant.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2020.104940.
Data availability
Differential expression analysis and raw data for the RNA-Seq are
deposited at NCBI Gene Expression Omnibus under the accessions
GSE133764 (CHCHD2 KO) and GSE133763 (CHCHD10 KO).
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